Anzeige
Mehr »
Login
Montag, 31.03.2025 Börsentäglich über 12.000 News von 695 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 662283 | ISIN: US80105N1054 | Ticker-Symbol: SNW2
Siehe auch SANOFI SA
Tradegate
31.03.25
20:10 Uhr
51,00 Euro
-1,00
-1,92 %
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
SANOFI SA ADR Chart 1 Jahr
5-Tage-Chart
SANOFI SA ADR 5-Tage-Chart
RealtimeGeldBriefZeit
51,0051,5021:58
51,0051,5021:57

Aktuelle News zur SANOFI SA ADR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
20:26Sanofi snags GSK's Chris Corsico to serve as global head of development9
16:46Sanofi's Qfitlia approved by FDA as first haemophilia therapy for all patients5
14:30FDA Approves Sanofi's Hemophilia Drug3
13:55Sanofi's Qfitlia granted FDA approval to treat haemophilia A or B4
FrSanofi Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors365Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors Qfitlia (fitusiran), the first antithrombin-lowering therapy in hemophilia, offers consistent...
► Artikel lesen
FrSanofi: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors193Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors Qfitlia (fitusiran), the first antithrombin-lowering therapy in hemophilia, offers consistent...
► Artikel lesen
SANOFI SA ADR Aktie jetzt für 0€ handeln
FrSanofi: FDA gibt grünes Licht - so reagieren die Aktien der Rivalen454Die US-Gesundheitsbehörde FDA hat am Freitag der Hämophilie-Therapie von Sanofi zugelassen. Dadurch ist der Weg für eine Behandlungsmethode für Patienten mit seltenen Blutgerinungsstörungen geebnet....
► Artikel lesen
FrFDA genehmigt Sanofis Hämophilie-Behandlung Qfitlia5
FrFDA approves Sanofi's hemophilia treatment Qfitlia4
FrSanofi gets FDA nod for its hemophilia treatment3
FrUS FDA approves Sanofi's bleeding disorder therapy5
FrAstraZeneca, Sanofi, Lilly, Pfizer CEOs meet with Xi Jinping amid US-China trade tensions38
FrSanofi Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD364Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results...
► Artikel lesen
FrSanofi: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD435Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results in adults...
► Artikel lesen
DoSanofi - S-8, Securities to be offered to employees in employee benefit plans11
DoFDA fast-tracks Sanofi's experimental chlamydia vaccine3
MiSanofi's Chlamydia Vaccine Candidate Gets FDA's Fast Track Tag5
MiFDA fast tracks Sanofi's mRNA vaccine for chlamydia4
MiSanofi's Chlamydia Vaccine Candidate Granted Fast Track Designation by FDA4
MiSanofi's investigational MS treatment tolebrutinib granted FDA priority review16
Seite:  Weiter >>
689 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1